BioMarin ( BioMarin )

BioMarin

BioMarin's picture

The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).

BioMarin press release, blog etc

12/11/2017 - 11:13 BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
12/09/2017 - 07:24 BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication
12/05/2017 - 22:09 BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition
11/27/2017 - 10:30 BioMarin Sells Second Priority Review Voucher for $125 Million
10/26/2017 - 08:22 FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
10/18/2017 - 14:41 BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
10/18/2017 - 07:41 Popular Science Names BioMarin's Brineura (cerliponase alfa) One of the Top Health Innovations of 2017 with "Best of What's New" Award
10/11/2017 - 08:05 BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
10/03/2017 - 05:44 BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
09/14/2017 - 12:06 FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA)
09/06/2017 - 08:31 BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017
09/05/2017 - 10:17 BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017
08/29/2017 - 16:21 FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation
08/23/2017 - 11:19 BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024
08/21/2017 - 11:08 Forbes Ranks BioMarin 12th Most Innovative Company in the World
08/07/2017 - 15:26 BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024
08/06/2017 - 20:03 BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
08/02/2017 - 12:11 BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies